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Initial experience with a stentless porcine bioprosthesis for right
ventricular outflow tract reconstruction in children
Luca A. Vricella, MD, Michael A. Coady, MD, and Michael D. Black, MD, Stanford, Calif
Postoperative pulmonary regurgitation and stenosis stillremain major determinants of long-term outcome in chil-dren requiring right ventricular outflow tract (RVOT)reconstruction.
Because of relatively low right-sided pressures, mechanical
valves are at high risk for thrombosis, and long-term anticoagula-
tion is disadvantageous in pediatric patients for obvious reasons.1
Because of accelerated calcification, bioprosthetic valves are, on
the other hand, likely to undergo structural valve deterioration in
younger patients.2
The use of a stentless valve design, with improved shear stress
on the valve leaflets, might prevent early valvular calcification.
The Toronto stentless porcine valve (SPV; St Jude Medical, Inc, St
Paul, Minn) incorporates a flexible Dacron ring with lack of an
accompanying aortic wall. We hypothesized that these distinguish-
ing characteristics might allow for improved long-term function
when used in RVOT reconstruction in children.
Clinical Summary
Nine patients (8 male patients and 1 female patient) born with
tetralogy of Fallot underwent RVOT reconstruction with Toronto
SPVs between March 1998 and July 2001. Mean age and weight
were, respectively, 11.2 years (range, 4-17 years) and 41.6 kg
(range, 15.2-83.1 kg). Preoperative patient characteristics and sur-
gical indications are summarized in Table 1. All but one procedure
were reoperative, with surgical indications being RVOT stenosis
(n  4) or pulmonary insufficiency (n  5). Intraoperative trans-
esophageal echocardiography was performed in all patients, and
transthoracic echocardiograms were obtained at various intervals
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Figure 1. Insertion of an SPV in the subannular position within the
RVOT before patch arterioplasty: A, mattress suture securing the
anterior SPV commissural post to the RVOT patch; B, sutures
spacing the posterior posts at 120° distance to protect the right
and left pulmonary ostia; C, continuous proximal suture. The
anterior 120° of the suture line are passed transversely across the
RVOT patch.
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after discharge. No antiaggregant or anticoagulation therapy was
used. Mean follow-up was 14.5 months (range, 2-38 months).
Prosthetic valve diameter ranged between 19 and 29 mm
(mean, 27 mm). Mean cardiopulmonary bypass time was 165
minutes. Three patients underwent additional ventricular septal
defect repair, and 7 required pericardial RVOT patch augmenta-
tion. One patient required intraoperative bilateral branch pulmo-
nary artery stenting and one aortic and tricuspid valve repair. All
patients were extubated in the operating room. Mean postoperative
hospital stay was 2.6  0.8 days. No structural valve deterioration
was evident at the latest echocardiographic examination, and mean
postoperative peak systolic RVOT gradient was 18  6 mm Hg.
There were no early or late postoperative complications or deaths,
and no intermediate-term reintervention was necessary for valve-
related complications.
Comment
Pulmonary valve replacement in children still remains a difficult
surgical challenge because no ideal valve substitute exists. The To-
ronto SPV bioprosthesis offers a better hemodynamic profile in the
aortic position than stented valves, resembling the hemodynamic
characteristics of an aortic homograft. At least in the aortic position,
stentless valves appear to outperform stented bioprostheses, and du-
rability beyond 10 years in a substantial number of patients is seen.3
Most of the intermediate-term data thus far acquired on this
particular bioprosthesis derives from aortic valve replacement and
not RVOT reconstruction. In the pulmonary circuit, where hemo-
dynamic stress is not as marked as in the left ventricular outflow
tract, long-term durability for SPVs should be expected.
Several points should be made with regard to the technique of
valve implantation (Figure 1). Orientation of the valve, with 1
anterior and 2 lateral posts, is important in avoiding obstruction of
the origin of the branch pulmonary arteries. The commissural posts
should ideally be spaced at 120° intervals. Because of the more
modest shear stress to which the valve is subject within the RVOT,
the suture line should be continuous along the entire proximal
circumference of the sewing ring, rather than along the commis-
sural posts, as usually performed while implanting SPVs in the
aortic position. Lastly, should an arterioplasty be necessary, a
pericardial patch can be easily incorporated into the suture line
because it runs along the anterior portion of the bioprosthesis. This
in turn allows for insertion of a prosthesis with optimal diameter.
When compared with other currently available mechanical
prostheses or other bioprosthetic valves, the SPV has several
advantages:
1. The lack of need for anticoagulation is intuitively a major
advantage when considering the use of the valve in pedi-
atric patients.
2. The low profile of the SPV and its pliability facilitate
insertion at various RVOT levels, either in the annular on
infra-annular position.
3. When compared with homografts, SPVs might disclose
less incidence of stenosis at long-term follow-up. The SPV
is in fact devoid of porcine aortic wall, which has been
found to predispose to premature dystrophic calcification
in the animal model.4
4. In the unlikely event of progressive valvular stenosis,
percutaneous balloon valvotomy might be an option.5
This initial experience with SPVs in reconstruction of an RVOT in
children has shown encouraging clinical results. With increased
follow-up, we speculate that insertion of an SPV might be appro-
priate in older children, in whom late degeneration of homografts
(valvular or conduit related) remains predictable. When the child
has adequate connection between the right ventricle and the pul-
monary artery, the SPV might represent a comparable alternative
to currently available options.6
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(mm) Additional procedures performed
Length of follow-up; result of
latest echocardiogram
1 7 22.8 22 RVOT patch 38 mo; no PI, RVOT PSG 25 mm Hg
2 4 15.2 19 VSD closure, RVOT patch 34 mo; no PI, RVOT PSG 25 mm Hg
3 17 83.1 29 RVOT patch 18 mo; trace PI, RVOT PSG 19 mm Hg
4 7 23.0 27 VSD closure 11 mo; trace PI, RVOT PSG 19 mm Hg
5 13 40.2 29 Intraoperative branch PA stenting 11 mo; mild PI, RVOT PSG 13 mm Hg
6 9 24.0 27 RVOT patch 10 mo; trace PI, RVOT PSG 15 mm Hg
7 16 81.4 29 RVOT patch 6 mo; trace PI, RVOT PSG 19 mm Hg
8 12 32.0 29 VSD closure, RVOT patch 2 mo; no PI, RVOT PSG 6 mm Hg
9 16 53.0 29 VSD closure, aortic-tricuspid
valve repair, RVOT patch
2 mo; trace PI, RVOT PSG 21 mm Hg
PI, Pulmonary insufficiency; VSD, ventricular septal defect; PSG, peak systolic gradient; PA, pulmonary artery.
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